Savara completes submission of the biologics license application (bla) to the u.s. food and drug administration (fda) for molbreevi* as a treatment for autoimmune pulmonary alveolar proteinosis (apap)

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has completed submission of the bla to the fda for molbreevi as a treatment for apap. “submission of the bla marks an important milestone for the company and the apap community,” said matt pauls, chair and chief executive officer, savara. “we believe this unprecedented body of data demonstrates molbreevi improves pulm.
SVRA Ratings Summary
SVRA Quant Ranking